UNSPSC 51413207: Sildenafil citrate

This classification denotes a cgmp phosphodiesterase inhibitor with the molecular formula C22H30N6O4S.C6H8O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BW9B0ZE037, chemically known as 1-((3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1h-pyrazolo(4,3-d)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methylpiperazine citrate (1:1) but more generally known as sildenafil citrate, which bears US NIH Compound Identifier 62853.

UNSPSC 51413207 Sildenafil citrate, a Commodity code, does not align with the recent state and local procurement activity in the source. The single opportunity posted under this code—City of Tampa Purchasing Department's April 2026 sealed-bid solicitation (26P00188) for Advanced Life Support Medications—requests four specific medications for Tampa Fire Rescue (Labetalol HCI, Epinephrine, Adenosine, and Diltiazem), none of which is sildenafil citrate. The code appears misapplied to this procurement, suggesting a tagging error at the issuing body or in the opportunity-posting system rather than genuine demand for sildenafil citrate at the state and local level.

The Tampa opportunity does provide a window into how municipalities procure emergency-response pharmaceuticals: sealed-bid format, firm pricing including freight to destination, nine-month minimum shelf life, rapid fulfillment (ten calendar days), and one-year terms with renewal options. The City applied a 5 percent Small Local Business Enterprise (SLBE) bid discount (capped at $10,000) and required OSHA Safety Data Sheet compliance and WCAG 2.2 accessibility documentation. The estimated contract value was $40,000. With no other opportunities posted under code 51413207, the code shows insufficient recent activity to characterize issuing-body mix, geographic concentration, or genuine market demand for sildenafil citrate in state and local procurement.